57
Peer-Reviewed Studies
8,000+
SCD Cases Examined
4
Consensus Organizations
~7%
Of Young SCD From MVP
1978–2025
Publication Span

Doctors: Start With These Three Papers

If you only have time to read three papers, these establish the scientific consensus:

#38 — EHRA Expert Consensus Statement (2022)
Sabbag A et al. Europace. 2022;24(12):1981–2003.
The definitive consensus document endorsed by EHRA, HRS, APHRS, and LAHRS. Officially defines arrhythmic MVP as a cause of VF and SCD. PubMed →
#1 — Basso et al. Landmark Autopsy Study (2015)
Basso C et al. Circulation. 2015;132(7):556–566.
650 young SCD cases: MVP was the sole cause in 7%. 100% had papillary muscle fibrosis. PubMed →
#21 — Sriram et al. Cardiac Arrest Survivors (2013)
Sriram CS et al. JACC. 2013;62(3):222–230.
Among "idiopathic" cardiac arrest survivors, bileaflet MVP was found in 42%. Coined "malignant bileaflet MVP syndrome." PubMed →

Executive Summary

Mitral valve prolapse (MVP) is now recognized by international expert consensus as a direct cause of ventricular fibrillation (VF) and sudden cardiac death (SCD). The mechanism is well-established: MVP causes regionalized myocardial fibrosis in the papillary muscles and inferobasal left ventricular wall through chronic mechanical stretch. This fibrosis creates electrical re-entry circuits. Premature ventricular contractions (PVCs) originating from the fibrotic papillary muscles and Purkinje tissue then trigger VF. Critically, this occurs even with mild or no significant mitral regurgitation.

MVP accounts for approximately 7% of all sudden cardiac deaths in young adults and up to 13% in young women. Among survivors of "idiopathic" cardiac arrest, bileaflet MVP has been found in up to 42%. The high-risk phenotype includes bileaflet myxomatous prolapse, mitral annular disjunction (MAD), T-wave inversions in inferior leads, complex ventricular ectopy, and late gadolinium enhancement (fibrosis) on cardiac MRI.

This association is endorsed by the European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), European Society of Cardiology (ESC), and the Asia Pacific Heart Rhythm Society (APHRS), published in Circulation, JACC, NEJM, JAMA Cardiology, and the European Heart Journal. The 57 studies below represent the complete body of evidence.

Section 1: Autopsy & Histopathology Studies

9 studies
These studies examined the hearts of people who died suddenly and found MVP with characteristic fibrosis as the sole identifiable cause of death.
1 Basso C, Perazzolo Marra M, Rizzo S, et al. "Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death."
Circulation. 2015;132(7):556–566.
THE LANDMARK STUDY. 650 young SCD cases (≤40 yrs): 43 had MVP as SOLE cause (7% of all SCD, 13% in women). VF was the arrest rhythm. 100% had papillary muscle fibrosis. 88% had inferobasal wall fibrosis. 70% bileaflet. Living MVP patients with complex VAs: LGE on CMR in 93%.
PubMed DOI
2 Chesler E, King RA, Edwards JE. "The myxomatous mitral valve and sudden death."
Circulation. 1983;67(3):632–639.
14 cases of sudden death attributable to dysrhythmias from myxomatous mitral valves. Ages 14–59 (mean 27), 11 female. No other cause found at autopsy.
PubMed
3 Dollar AL, Roberts WC. "Morphologic comparison of patients with mitral valve prolapse who died suddenly."
J Am Coll Cardiol. 1991;17(4):921–931.
56 MVP patients at necropsy: 15 died suddenly with isolated MVP as the only finding. Younger, predominantly female.
JACC
4 Han HC, Parsons SA, Teh AW, et al. "Characteristic Histopathological Findings and Cardiac Arrest Rhythm in Isolated Mitral Valve Prolapse and Sudden Cardiac Death."
J Am Heart Assoc. 2020;9(7):e015587.
Australian nationwide 17-year study. VF was the initial arrest rhythm in 94% of witnessed cases. Fibrosis subendocardial-midmural in 85%.
PubMed
5 Westaby JD, Bicalho L, Zullo E, Sheppard MN. "Insights into malignant mitral valve degenerative disease from a sudden cardiac death cohort."
Histopathology. 2024;84(2):320–331.
LARGEST AUTOPSY SERIES. 8,108 SCD cases → 120 (1.5%) had MVP. Ventricular fibrosis in 90%.
PubMed DOI
6 Hourdain J, Clavel MA, Deharo JC, et al. "Common Phenotype in Patients With Mitral Valve Prolapse Who Experienced Sudden Cardiac Death."
Circulation. 2018;138(9):1067–1069.
22 SCD victims with MVP: young women, bileaflet prolapse, PVCs of papillary muscle/fascicular origin, inferolateral T-wave inversions.
PubMed
7 Pocock WA, Bosman CK, Chesler E, et al. "Sudden death in primary mitral valve prolapse."
Am Heart J. 1984;107(2):378–382.
SCD can be the FIRST clinical manifestation of MVP in otherwise healthy individuals.
PubMed
8 Narayanan K, Uy-Evanado A, Teodorescu C, et al. "Mitral valve prolapse and sudden cardiac arrest in the community."
Heart Rhythm. 2016;13(2):498–503.
Oregon POST SCD study: MVP in ~4% of community sudden arrhythmic deaths. Myocardial fibrosis in ALL MVP cases.
PubMed
9 Ackerman JP, Bartos DC, Bhatt AB, et al. "Prevalence and potential genetic determinants of young sudden unexplained death victims with suspected arrhythmogenic mitral valve prolapse syndrome."
Heart Rhythm. 2022;19(3):476–484.
Molecular autopsy of 77 sudden unexplained deaths. MVP was the lone abnormality in 7.8%, ALL with LV fibrosis. No alternative genetic cause found.
PubMed

Section 2: Cardiac MRI Studies — The Arrhythmogenic Substrate

10 studies
These studies identify the fibrosis (scar) that creates the electrical substrate for VF in living MVP patients using cardiac magnetic resonance imaging.
10 Perazzolo Marra M, Basso C, De Lazzari M, et al. "Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse."
Circ Cardiovasc Imaging. 2016;9(8):e005030.
MAD significantly greater in arrhythmic MVP (4.8 vs 1.8 mm). Posterior systolic curling in 94% with LGE vs 19% without. MAD + curling → mechanical stretch → fibrosis.
PubMed
11 Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, et al. "Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse."
Circulation. 2021;143(18):1763–1774.
400 MVP patients. LGE in 28%. Even in trace-to-mild MR, 13% had LGE and 25% had VA. Fibrosis and arrhythmias occur WITHOUT significant regurgitation.
PubMed
12 Figliozzi S, Georgiopoulos G, Gatti M, et al. "Myocardial Fibrosis at Cardiac MRI Helps Predict Adverse Clinical Outcome in MVP."
Radiology. 2023;306(1):112–121.
LARGEST multicenter CMR study (474 patients, 15 centers). LGE → HR 4.2 for adverse arrhythmic events.
PubMed
13 Kitkungvan D, Nabi F, Kim RJ, et al. "Myocardial Fibrosis in Patients With Primary Mitral Regurgitation With and Without Prolapse."
JACC. 2018;72(8):823–834.
MVP patients had higher fibrosis than non-MVP MR patients. This fibrosis is UNIQUE TO MVP — not from volume overload.
JACC
14 Nagata Y, Bertrand PB, Baliyan V, et al. "Abnormal Mechanics Relate to Myocardial Fibrosis and Ventricular Arrhythmias in MVP."
Circ Cardiovasc Imaging. 2023;16:e014963.
113 MVP patients. Fibrosis in 38%. Novel "double-peak strain" pattern independently predicted arrhythmic events.
PubMed
15 Tang X, Fan W. "LGE by Cardiac MRI and Ventricular Arrhythmia in MVP: A Systematic Review and Meta-Analysis."
Clin Cardiol. 2024;47:e24316.
Meta-analysis: LGE strongly and consistently associated with VA in MVP.
PubMed
16 Bui AH, Roujol S, Foppa M, et al. "Diffuse myocardial fibrosis in patients with mitral valve prolapse and ventricular arrhythmia."
Heart. 2017;103:204–209.
Diffuse interstitial fibrosis (T1 mapping) was the ONLY predictor of arrhythmias.
PubMed
17 Miller MA, Devesa A, Robson PM, et al. "Arrhythmic MVP With Only Mild or Moderate MR: Characterization of Myocardial Substrate."
JACC Clin Electrophysiol. 2023;9:1709–1716.
PET/MRI: 83% showed active inflammation coexisting with fibrosis. Arrhythmias occur with MILD MR.
PubMed
48 Perazzolo Marra M, Cecere A, Cipriani A, et al. "Determinants of Ventricular Arrhythmias in Mitral Valve Prolapse."
JACC Clin Electrophysiol. 2024;10(4):670–681. NEW
Major study from the Padua group. Identified that LGE extent and location (not just presence), MAD, and bileaflet prolapse are independent determinants of VA in MVP. Fibrosis in papillary muscles AND inferobasal wall had the highest arrhythmic risk.
PubMed DOI
49 Ermakov S, Gulhar R, Lim L, et al. "Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse."
Heart. 2019;105(14):1063–1069. NEW
LV mechanical dispersion by speckle-tracking echocardiography independently predicted complex VA in MVP patients, providing a noninvasive risk stratification tool.
PubMed

Section 3: How MVP Causes Fibrosis That Causes VF

3 studies
MVP → abnormal mechanical stretch → regionalized fibrosis → electrical re-entry circuits → VF.
18 Morningstar JE, Nieman A, Wang C, et al. "Mitral Valve Prolapse Induces Regionalized Myocardial Fibrosis."
J Am Heart Assoc. 2021;10(24):e022332.
PROVES MVP DIRECTLY CAUSES FIBROSIS. Human biopsies + mouse model. Fibrosis with activated myofibroblasts in peripapillary zone. MVP mouse → progressive fibrosis. Mechanical stretch activated profibrotic genes in vitro.
PubMed
19 Hutchins GM, Moore GW, Skoog DK. "The association of floppy mitral valve with disjunction of the mitral annulus fibrosus."
N Engl J Med. 1986;314:535–540.
Original description of mitral annular disjunction (MAD) associated with floppy mitral valve.
PubMed
20 Dejgaard LA, Skjølsvik ET, Lie ØH, et al. "The Mitral Annulus Disjunction Arrhythmic Syndrome."
JACC. 2018;72(14):1600–1609.
116 MAD patients: one-third had VA, 10% severe arrhythmic events. 22% with MAD did NOT have MVP — arrhythmias occurred regardless.
PubMed

Section 4: Cardiac Arrest Survivors with MVP

7 studies
Studies of patients who survived sudden cardiac arrest and MVP was identified as the cause.
21 Sriram CS, Syed FF, Ferguson ME, et al. "Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest."
JACC. 2013;62(3):222–230.
LANDMARK. 24 "idiopathic" arrest survivors → bileaflet MVP in 42%. ONLY bileaflet MVP predicted VF recurrence (OR 7.2). 54% received appropriate ICD shocks for VF within 1.8 years. Coined "malignant bileaflet MVP syndrome."
PubMed
22 Chakrabarti A, Giudicessi JR, Ezzeddine FM, et al. "Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest."
Circ Arrhythm Electrophysiol. 2025;18(3):e013099.
LARGEST REGISTRY: 148 patients from 21 centers who survived SCA or had sustained VT/VF attributed to MVP. Mean age 43.7, 68% women, 73% bileaflet, 65% MAD.
PubMed
23 Essayagh B, Sabbag A, Antoine C, et al. "Presentation and Outcome of Arrhythmic Mitral Valve Prolapse."
JACC. 2020;76(6):637–649.
595 MVP patients. Severe arrhythmia associated with MAD, leaflet redundancy, T-wave inversions — NOT with MR severity or EF. Severe VA predicted excess mortality (HR 2.94).
PubMed
24 Wei JY, Bulkley BH, Schaeffer AH, et al. "Mitral-valve prolapse syndrome and recurrent ventricular tachyarrhythmias: a malignant variant refractory to conventional drug therapy."
Ann Intern Med. 1978;89(1):6–9.
17% of patients with drug-refractory VT had MVP. Four had survived VF. One of the earliest identifications of the "malignant variant."
PubMed
50 Alqarawi W, Tadros R, Roberts JD, et al. "The Prevalence and Characteristics of Arrhythmic Mitral Valve Prolapse in Patients With Unexplained Cardiac Arrest."
JACC Clin Electrophysiol. 2023;9(12):2494–2503. NEW
Canadian Cardiac Arrest Survivors registry. AMVP was identified in 16% of patients with unexplained cardiac arrest. Highlights that AMVP is significantly underdiagnosed as a cause of cardiac arrest.
PubMed
51 Groeneveld SA, Kirkels FP, Cramer MJ, et al. "Prevalence of Mitral Annulus Disjunction and Mitral Valve Prolapse in Patients With Idiopathic Ventricular Fibrillation."
J Am Heart Assoc. 2022;11(16):e025364. NEW
MAD was present in 29% of idiopathic VF patients vs 4% of controls (P<0.001). MVP was found in 18% of idiopathic VF patients. Establishes MAD/MVP as a significant unrecognized substrate in "idiopathic" VF.
PubMed
52 Jaworski K, Kowalik I, Firek B, et al. "Mitral valve prolapse in sudden cardiac arrest survivors: Coincidence or causal relationship?"
Heart Rhythm. 2025;22(10):2447–2456. NEW
Compared SCA survivors with MVP to those without. MVP patients had more frequent VF as the presenting rhythm, more papillary muscle fibrosis on CMR, and higher arrhythmic recurrence — supporting a causal rather than coincidental association.
PubMed

Section 5: Large Cohort & Epidemiological Studies

7 studies
Population-level studies quantifying MVP-associated SCD risk in large patient groups.
25Nishimura RA, McGoon MD, Shub C, et al. "Echocardiographically documented MVP: Long-term follow-up of 237 patients."
N Engl J Med. 1985;313(21):1305–1309.
Mayo Clinic. Redundant leaflets → 10.3% had SCD/endocarditis/embolic events vs 0.7% (P<0.001).
PubMed
26Freed LA, Levy D, Levine RA, et al. "Prevalence and clinical outcome of mitral-valve prolapse."
N Engl J Med. 1999;341(1):1–7.
Framingham Study. MVP prevalence 2.4%. Classic MVP associated with complications including SCD.
PubMed
27Avierinos JF, Gersh BJ, Melton LJ, et al. "Natural history of asymptomatic mitral valve prolapse in the community."
Circulation. 2002;106(11):1355–1361.
833 asymptomatic MVP patients. SCD risk confirmed in community-based longitudinal follow-up.
PubMed
28Nordhues BD, Siontis KC, Scott CG, et al. "Bileaflet mitral valve prolapse and risk of ventricular dysrhythmias and death."
J Cardiovasc Electrophysiol. 2016;27(4):463–468.
>5,000 patients. Bileaflet MVP → more VT (HR 1.48).
PubMed
29Essayagh B, Sabbag A, Antoine C, et al. "The Mitral Annular Disjunction of MVP: Presentation and Outcome."
JACC Cardiovasc Imaging. 2021;14(11):2073–2087.
MAD → arrhythmic events HR 2.60. Risk PERSISTED after surgery (HR 2.07).
PubMed
53Zuin M, Rigatelli G, Bilato C. "Sudden Cardiac Death in Patients With Mitral Valve Prolapse in US (1999–2020)."
Am J Cardiol. 2023;193:34–36. NEW
CDC WONDER database: 824 US subjects with MVP died from SCD between 1999–2020. Higher mortality in women <44 years. Confirms demographic risk profile in a large US population dataset.
PubMed
54Sabbag A, Aabel EW, Castrini AI, et al. "Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum."
Eur Heart J. 2024;45(20):1831–1839. NEW
Multicenter study of AMVP women. Pregnancy and early postpartum carry increased arrhythmic risk in women with arrhythmic MVP, with ventricular arrhythmia events clustering around delivery.
PubMed

Section 6: Electrophysiology & Ablation Studies

5 studies
Invasive studies directly mapping VF origin to MVP-damaged tissue, and ablation outcomes.
30Syed FF, Ackerman MJ, McLeod CJ, et al. "Sites of Successful Ventricular Fibrillation Ablation in Bileaflet MVP."
Circ Arrhythm Electrophysiol. 2016;9(5):e004005.
VF ablation targets: papillary muscles, Purkinje system, LVOT — same regions where autopsy found fibrosis.
PubMed
31Enriquez A, Shirai Y, Huang J, et al. "Papillary muscle ventricular arrhythmias in patients with arrhythmic MVP."
J Cardiovasc Electrophysiol. 2019;30(6):827–835.
39% of patients with papillary muscle VAs had MVP vs 0% at other sites (P<0.001).
PubMed
32Chakrabarti AK, Deshmukh A, Liang JJ, et al. "Mitral Annular Substrate and Ventricular Arrhythmias in Arrhythmogenic MVP With MAD."
JACC Clin Electrophysiol. 2023;9(8):1265–1275.
Low voltage (scar) found at mitral annulus in ALL VT patients with bileaflet MVP and MAD.
PubMed
33Marano PJ, Lim LJ, Sanchez JM, et al. "Long-term outcomes of ablation for ventricular arrhythmias in MVP."
J Interv Card Electrophysiol. 2021;61(1):145–154.
15 MVP patients post-ablation: 33% developed VT/VF requiring ICD at 9 years. Progressive substrate.
PubMed
55Aabel EW, Chivulescu M, Lie ØH, et al. "Ventricular arrhythmias in arrhythmic mitral valve syndrome — a prospective continuous long-term cardiac monitoring study."
Europace. 2023;25(2):506–516. NEW
Prospective long-term monitoring of MVP patients with implantable loop recorders. Detected significantly more arrhythmias than Holter monitoring — supporting that arrhythmic burden in MVP is underestimated by conventional monitoring.
PubMed

Section 7: Systematic Reviews & Meta-Analyses

4 studies
Pooled evidence from multiple studies confirming the MVP-SCD association.
34Han HC, Ha FJ, Teh AW, et al. "Mitral Valve Prolapse and Sudden Cardiac Death: A Systematic Review."
J Am Heart Assoc. 2018;7(23):e010584.
161 MVP-SCD cases. Median age 30, 69% female, VF in 81%, bileaflet 70%, non-severe MR 83%.
PubMed
35Nalliah CJ, Mahajan R, Elliott AD, et al. "Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis."
Heart. 2019;105(2):144–151.
Meta-analysis of 34 studies. MVP found in 11.7% of undetermined SCD. Annual SCD incidence in MVP: 0.14%.
PubMed
36Pistelli L, Vetta G, Parlavecchio A, et al. "Arrhythmic risk profile in MVP: A systematic review and metanalysis of 1715 patients."
J Cardiovasc Electrophysiol. 2024;35(2):290–300.
Bileaflet prolapse, MAD, LGE, and T-wave inversions = strongest predictors of complex VA.
PubMed
37Gatti M, Santonocito A, Papa FP, et al. "Role of cardiac MRI in stratifying arrhythmogenic risk in MVP: systematic review and meta-analysis."
Eur Radiol. 2024;34(11):7321–7333.
LGE = strongest CMR predictor of complex VA in MVP.
PubMed

Section 8: Expert Reviews & Society Consensus Statements

8 studies
Official positions from EHRA, ESC, HRS, and leading experts confirming MVP as a recognized cause of SCD.
38Sabbag A, Essayagh B, Barrera JDR, et al. "EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex."
Europace. 2022;24(12):1981–2003.
THE KEY CONSENSUS DOCUMENT. Endorsed by HRS, APHRS, LAHRS. Officially defines arrhythmic MVP as causing VF and SCD. Show this to your doctors.
PubMedDOI
39Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. "2022 ESC Guidelines for management of patients with ventricular arrhythmias and prevention of SCD."
Eur Heart J. 2022;43(40):3997–4126.
ESC guidelines: dedicated section recognizing MVP as a cause of SCD.
PubMed
40Basso C, Iliceto S, Thiene G, Perazzolo Marra M. "Mitral Valve Prolapse, Ventricular Arrhythmias, and Sudden Death."
Circulation. 2019;140(11):952–964.
State-of-the-art review from the world's leading researchers on arrhythmic MVP (Padua group).
PubMed
41Miller MA, Dukkipati SR, Turagam MK, et al. "Arrhythmic Mitral Valve Prolapse: JACC Review Topic of the Week."
JACC. 2018;72(23):2904–2914.
Substrate-trigger model: fibrosis + PVCs from papillary muscles = VF.
PubMed
42Muthukumar L, Jahangir A, Jan MF, et al. "Association Between Malignant MVP and Sudden Cardiac Death: A Review."
JAMA Cardiol. 2020;5(9):1053–1061.
~26,000 individuals in the US may be at risk of SCD per year from malignant MVP.
PubMed
43Essayagh B, Sabbag A, El-Am E, et al. "Arrhythmic MVP and MAD: pathophysiology, risk stratification, and management."
Eur Heart J. 2023;44(33):3121–3135.
European Heart Journal state-of-the-art review.
PubMed
44Delling FN, Noseworthy PA, Adams DH, et al. "Research Opportunities in the Treatment of MVP: JACC Expert Panel."
JACC. 2022;80(24):2331–2347.
0.4%–1.8% annual SCA/SCD risk in MVP. 32,000–152,000 potential SCA events/year in the US.
PubMed
56L'Hoyes W, Robyns T, Moura-Fereira S, et al. "Effectiveness of the risk stratification proposed by the 2022 EHRA Expert Consensus statement on arrhythmic MVP."
Am Heart J. 2023;266:48–60. NEW
Validated the 2022 EHRA consensus risk stratification approach. The EHRA-proposed high-risk features effectively identified patients who went on to have arrhythmic events, supporting use of the consensus framework in clinical practice.
PubMed

Section 9: Surgery Studies

4 studies
Does fixing the valve eliminate arrhythmic risk? Not entirely — once fibrosis has formed, risk persists.
45Vaidya VR, DeSimone CV, Damle N, et al. "Reduction in malignant VA following surgical correction of bileaflet MVP."
J Interv Card Electrophysiol. 2016;46(2):137–143.
MV repair reduced VA and ICD shocks. Surgery helps but is adjunctive.
PubMed
46Lodin K, Da Silva CO, Wang Gottlieb A, et al. "MAD and MVP: long-term risk of ventricular arrhythmias after surgery."
Eur Heart J. 2025;46(28):2795–2805.
MAD → 3-fold increased VA risk AFTER surgery (HR 3.33). Fibrosis is NOT eliminated by surgery.
PubMed
47Essayagh B, Sabbag A, Antoine C, et al. "The Mitral Annular Disjunction of MVP: Presentation and Outcome."
JACC Cardiovasc Imaging. 2021;14(11):2073–2087.
Arrhythmic risk from MAD persisted after surgery (HR 2.07). Surgery fixes the valve but not the fibrosis.
PubMed
57Ezzeddine FM, Shin JWJ, Siontis KC, et al. "Outcomes in Patients With Mitral Annular Disjunction and an Implantable-Cardioverter Defibrillator."
J Cardiovasc Electrophysiol. 2025;36(5):1014–1021. NEW
Mayo Clinic study of ICD outcomes in MAD patients. 42% received appropriate ICD therapy for VT/VF during follow-up, confirming the ongoing arrhythmic risk and validating ICD use in this population.
PubMed